Jun 16, 2026 04:30PM
Jun 16, 2026 04:30PM
Jun 4, 2026 10:09AM
Jun 4, 2026 10:09AM
Jun 2, 2026 07:01AM
Jun 2, 2026 07:01AM
May 27, 2026 04:05PM Travere receives patent allowance for FILSPARI use in kidney disease
May 27, 2026 04:05PM
May 4, 2026 04:01PM
Apr 24, 2026 06:45AM
Apr 14, 2026 07:08AM
Apr 14, 2026 07:00AM
Apr 14, 2026 07:00AM
Apr 14, 2026 06:47AM H.C. Wainwright Reiterates Buy Rating on Travere Therapeutics (TVTX)
Apr 13, 2026 06:16PM
Apr 13, 2026 06:16PM
Feb 19, 2026 04:01PM
Jan 16, 2026 01:20PM
Jan 14, 2026 06:48AM
Jan 13, 2026 01:24PM
Jan 13, 2026 01:24PM Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS
Jan 13, 2026 07:27AM
Jan 13, 2026 04:57AM
Jan 12, 2026 05:00PM
Jan 12, 2026 05:00PM
Dec 24, 2025 11:54AM
Nov 6, 2025 11:00AM
Nov 6, 2025 11:00AM Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025
Oct 30, 2025 04:01PM
Oct 17, 2025 09:01AM
Sep 26, 2025 07:02AM
Sep 26, 2025 07:00AM
Sep 11, 2025 06:48AM
Sep 10, 2025 10:30AM
Sep 10, 2025 10:11AM Stifel Reiterates Hold Rating on Travere Therapeutics (TVTX)
Sep 10, 2025 09:58AM
Sep 10, 2025 07:01AM
Sep 10, 2025 07:01AM
Sep 3, 2025 07:01AM
Aug 28, 2025 07:33AM
Aug 27, 2025 05:09PM
Aug 27, 2025 05:09PM Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy
Aug 6, 2025 04:01PM
Jul 6, 2025 10:00AM
Jul 1, 2025 10:00AM
Jun 28, 2025 10:00AM
Jun 23, 2025 11:55AM
Jun 18, 2025 12:13PM
Jun 15, 2025 10:00AM INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
Jun 11, 2025 07:01AM

323,577 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All